Biotechnology In the next three months, the National Health Service (NHS) will start providing Sanofi’s Kevzara (sarilumab) for routine use in combination with methotrexate (MTX) for English patients with severe, active rheumatoid arthritis who have responded inadequately to intensive therapy with conventional or other disease modifying anti-rheumatic drugs and who cannot have rituximab. 2 November 2017